Hutchison MediPharma, the drug discovery arm of Chi-Med, has begun a first-in-human Phase I clinical trial of epitinib (HMPL-813), the third of MediPharma’s oncology compounds to enter clinical testing. Epitinib is a novel, second generation, orally active, small molecule inhibitor targeting the epidermal growth factor receptor (EGFR). MediPharma hopes epitinib will prove to be effective against brain tumors that have EGFR mutations, either primary brain tumors or tumors metastasized to the brain. More details....

Stock Symbol: (AIM: HCM)     Share this with colleagues: